Lysozyme modulates inflammatory responses to exacerbate the severity of rheumatoid arthritis

LYZ is highly expressed in the plasma and synovial fluid macrophages of early RA patients and exacerbates RA progression by modulating inflammation-related pathways, demonstrating potential as a biomarker for early RA diagnosis or a therapeutic target.